Our Stocks to Watch tomorrow include IDM Pharma, Inc. (NASD: IDMI), Paivis Corporation (OTCBB: PAVCE), AmeriResource Technologies, Inc. (OTCBB: ARRT), Purple Beverage Company, Inc. (OTCBB: PPBV), S3 Investment Company, Inc. (OTC: SIVC) and Vasomedical, Inc. (OTC: VASO).
Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
IDM PHARMACEUTICALS INCORPORATED (NASD: IDMI)
"Up 234.21% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/IDMI.php
IDM Pharma, Inc., a biopharmaceutical company, engages in the development of products to treat and control cancer. The company primarily develops product candidates to destroy residual cancer cells, as well as product candidates to stimulate an immune response and prevent tumor recurrence. Its products include Junovan, an immune system stimulant, which completed phase III study for the treatment of osteosarcoma; Bexidem, a cell-based immunotherapeutic, which is in phase II trials for the treatment of bladder cancer; and Uvidem, which is in Phase II clinical trials for the treatment of melanoma, consists of dendritophages and melanoma tumor cell lysates. The company's products also include EP-2101, which has multiple tumor-associated CTL epitopes, is in Phase II trials for the treatment of non-small cell lung cancer; and Collidem, which is in Phase I/II trails for the treatment of Colorectal cancer, consists of dendritophages and tumor associated antigen peptides. It operates in the United States and France. IDM Pharma has collaboration agreements with sanofi-aventis S.A; Medarex, Inc.; GenPharm International, Inc.; Novartis; and Biotecnol S.A. The company is based in Irvine, California.
IDMI News:
February 4 - IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Children's Oncology Group Report Shows the Addition of L-MTP-PE to Chemotherapy Reduced the Risk of Death by 30% in Osteosarcoma Patients
IDM Pharma, Inc. (NASD: IDMI) announced the Journal of Clinical Oncology (JCO) has published findings from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133), entitled "Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival - A Report from the Children's Oncology Group." The landmark clinical trial, which is the largest study completed in this disease was a National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG).
The COG's findings were based on long-term follow up of 662 patients with newly diagnosed non-metastatic osteosarcoma treated in the Phase 3 trial and demonstrated that the addition of L-MTP-PE to chemotherapy following surgery resulted in statistically superior Overall Survival (OS) the first stated aim of the study.
In the past two decades, there have been no treatment advances for patients with osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
"L-MTP-PE in combination with chemotherapy has demonstrated a significant long-term overall survival advantage in the largest Phase 3 clinical trial completed in patients with osteosarcoma," said Dr. Paul Meyers, vice chair, department of pediatrics at Memorial Sloan-Kettering Cancer Center and principal investigator of the Phase 3 trial. "These results are encouraging for children and young adults with osteosarcoma, considering the lack of progress for these patients in the last 20 years."
The JCO publication highlighting long-term follow up from this study formed the basis of the recent oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), regarding the Marketing Authorization Application (MAA) for L-MTP-PE for the treatment of patients with non-metastatic, resectable osteosarcoma. Updated results from this study were previously presented at the Connective Tissue Oncology Society (CTOS) annual meeting in November 2007. In addition, the new JCO publication highlights the long-term OS data whereas a prior JCO publication in 2005 focused on an Event Free Survival (EFS) additional analysis.
"These findings of statistically superior overall survival in long-term patient follow-up validate the survival benefit offered by L-MTP-PE and underscore the desperate need for new treatments for osteosarcoma patients," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We believe these findings were critical to the recent opinion from the Committee for Medicinal Products for Human Use in Europe and are a positive step toward bringing this important treatment to the European market and potentially gaining approval in the United States."
Study design and findings:
The multicenter, open label, randomized, factorial, four parallel treatment group Phase 3 study was designed to evaluate the effects of patient outcome of the addition of L-MTP-PE to three-drug chemotherapy (cisplatin, doxorubicin, and methotrexate) or four-drug-chemotherapy (cisplatin, doxorubicin, methotrexate, and ifosfamide) in patients with newly diagnosed resectable osteosarcoma without metastatic disease.
Patients received one of four prospectively randomized treatments and all patients received identical cumulative doses of cisplatin, doxorubicin, and methotrexate and underwent definitive surgical resection of primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2x2 factorial design.
In the published analysis, the chemotherapy regimens without L-MTP-PE resulted in similar OS and EFS. Overall Survival after six years of follow-up in patients treated with chemotherapy and L-MTP-PE was 78%, compared to 70% in patients treated only with chemotherapy (p=0.03). The addition of L-MTP-PE to chemotherapy resulted in approximately 30% decrease in the risk of death. EFS, an additional analysis which includes the occurrence of secondary malignancies, after six years of follow-up in patients treated with chemotherapy and L-MTP-PE was 67% compared to 61% in patients treated only with chemotherapy (p=0.08).
Treatment with L-MTP-PE was generally well tolerated in all phases of study. Adverse events were mild to moderate in severity and included chills, fever, nausea, vomiting, myalgia, headache, tachycardia (fast heart rate), hypo- and hypertension, fatigue and shortness of breath, all of which are consistent events with the activation of monocytes and macrophages by L-MTP-PE and the flu-like symptoms that follow cytokine release. These side effects are readily prevented or treated with acetaminophen.
L-MTP-PE Regulatory Status:
The Company recently announced that following presentation of data at an oral explanation hearing before the CHMP, the Committee determined in a non-binding opinion that L-MTPE-PE suggested a possible clinical benefit in terms of survival and granted the Company a clock stop, or time extension. The clock stop will allow the Company additional time to respond to all the remaining questions regarding the MAA.
The CHMP has requested clarification of the existing data in order to gain assurance about the quality of the data before drawing any final conclusions from the data presented. In addition, the Company is required to address a number of remaining questions relating to chemistry, manufacturing and controls (CMC). The Company now expects to receive a final opinion from the CHMP in the third quarter and a final decision from the European Commission in the fourth quarter of 2008.
L-MTP-PE was granted orphan drug status in Europe in 2004. The MAA for L-MTP-PE was submitted to the EMEA and accepted for review in November 2006.
As previously announced, in the United States the Company continues to work with COG as well as external experts and advisors to gather patient follow up data from the Phase 3 clinical trial of L-MTP-PE conducted by COG and to respond to other questions in the not approvable letter the Company received from the U.S. Food and Drug Administration (FDA).
L-MTP-PE was granted orphan drug status in the United States in 2001. The new drug application (NDA) for L-MTP-PE was submitted to FDA in October 2006 and was accepted for review in December 2006.
ABOUT OSTEOSARCOMA
About 3 percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.
Osteosarcoma is an orphan disease with fewer than 1,000 new cases diagnosed in the U.S. each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group, the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
PAIVIS CORPORATION (OTC BB: PAVCE)
"Up 115.38% on Tuesday" Detailed Quote: http://www.otcpicks.com/quotes/PAVCE.php
Paivis Corp., a facility-based wholesale telecommunications carrier, delivers application/value-added services in the prepaid services market. It sells telecommunications products and services, such as prepaid calling cards, prepaid wireless service, and international wholesale terminations. The company also owns and operates a carrier-class prepaid calling platform, including 2 NACT phone card switches integrated with the voice over Internet protocol system dedicated to domestic and international termination and origination of calls. As of September 30, 2006, the company's products are sold through approximately 3,000 retail outlets in the United States. Paivis Corp. is headquartered in Atlanta, Georgia.
PAVCE News:
February 5 - TRUSTCASH HOLDINGS, INC. and PAIVIS, CORP. Announce Signing of Amended and Restated Definitive Agreement and Plan of Merger; Paivis Shareholders to Receive $0.10/Share in Cash Plus One Share of TRUSTCASH Common Stock
Trustcash Holdings, Inc. ("TRUSTCASH") (OTCBB: TCHH) and Paivis Corporation (OTCBB: PAVCE) ("PAIVIS") jointly announced their execution of a Amended and Restated Definitive Agreement and Plan of Merger (the "Merger Agreement") pursuant to which TRUSTCASH has agreed, through a wholly-owned subsidiary, to acquire 100% of the issued and outstanding common shares of PAIVIS, and PAIVIS has agreed, at the closing of the transaction, to become a wholly-owned subsidiary of TRUSTCASH. As consideration in the merger transaction, TRUSTCASH has agreed to pay $0.10/share in cash plus one share TRUSTCASH common stock for each common share held by PAIVIS shareholders.
Greg Moss, the Chief Executive Officer of TRUSTCASH, commented, "We are pleased to complete this amended Merger Agreement to the benefit of the shareholders. We believe Paivis is very important for this future of this company and we believe this new structure is not only simpler but very positive for all involved. We look forward to completing the next steps towards becoming one great company."
Edwin Kwong, the Interim Chief Executive Officer of PAIVIS, commented further, "With the signing of the new Amended Merger Agreement we feel we have achieved a much simpler transaction that still provides quality value to our shareholders. We have said before, and still believe that the future of the combined corporations holds a lot of potential for value creation for our shareholders."
The parties have agreed to use their best efforts to consummate the transaction by March 31, 2008, or as soon as practicable thereafter.
The Merger Agreement, which includes all details of the transaction, will be filed by TRUSTCASH and PAIVIS as an exhibit to a Current Report on Form 8-K with the U.S. Securities and Exchange Commission as required. The Merger Agreement contains certain conditions precedent to consummation of the merger and customary subjects, including but not limited to the audits of Paivis and its acquisitions being completed, financing being secured by Trustcash respective shareholder approval, obtaining consents, providing certified lists of shareholders and delivery of certain due diligence and other corporate documents.
ABOUT TRUSTCASH
Through its Trustcash brand and website www.Trustcash.com, the Company is a pioneer of anonymous payment systems for the internet. It developed a business based on the sale of a stored value card (both virtual and physical) that can be used by consumers to make secure and anonymous purchases on the internet without disclosing their credit card or personal information. Trustcash provides to its customers the "Trustcash(TM)" payment card, which is sold in denominations ranging from $10 to $200 either online, through any of over 500 websites, or at over 50,000 retail locations in the United States via MoneyGram. Trustcash's non-reloadable, virtual Trustcash card is the only "stored value card" that can be purchased where no personal data is stored or available, providing a unique level of both security and privacy to the purchaser.
AMERIRESOURCE TECHNOLOGIES (OTCBB: ARRT)
"Up 50.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/ARRT.php
AmeriResource Technologies, Inc., through its subsidiaries, operates online auction drop-off locations that enables online sale of goods on eBay. As of March 31, 2007, the company operated 8 drop-off locations, as well as 25 affiliate locations. It also develops self-serve/checkout systems that enable customers of fast-food and take-out restaurants to place their food and beverage orders and pay with cash or a credit/debit card; and provides software design and product development for commercial business users doing business on eBay. The company also provides eBay liquidation services for excess inventory, overstock items, and merchandise that has been returned to the retailer; and conducts sales on eBay for the customers. In addition, it provides voice over Internet protocol (IP) communications solutions and IP communications devices. The company was incorporated in 1989 and is based in Las Vegas, Nevada.
ARRT News:
February 4 - AmeriResource Update: BizAuctions Revenues for January 2008 Increase by 335%
AmeriResource Technologies, Inc. (OTCBB: ARRT), a diversified holding company, announced that January revenues (unaudited) for its subsidiary, BizAuctions, Inc., increased by approximately 335% over revenues for the same period in 2007.
"For the month ending January 31, 2008, revenues (unaudited) have increased to approximately $386,495 from approximately $88,844, an increase of $297,651 or 335% over the corresponding month in 2007. BizAuctions' eBay business model continues to demonstrate strong and steady growth while the Company broadens its operations. Management has made great strides in increasing gross profits while reducing monthly operating expenses and has not realized net profits on a consistent basis," comments Delmar Janovec, CEO of AmeriResource.
"BizAuctions employs two primary business models, whereby it liquidates inventory through eBay on consignment for a lucrative commission; and/or it purchases inventory at a fraction of retail price for the purpose of liquidating it for a profit. BizAuctions consigns, buys inventory, and liquidates through eBay," continues Janovec.
BizAuctions' clients have included some of the Nation's leading retail names at the forefront of their industries. With a long-term strategy to provide eBay liquidation services to Fortune 1000 enterprises, BizAuctions is a clear and lucrative solution for most any business to liquidate excess inventory on eBay.
BizAuctions' operations are designed for maximum capacity to handle most any eBay liquidation project. Whether the client is a Fortune 500 company with 1,000 items or a small business with 100 items, BizAuctions can take on most any project and recover funds from clients' excess inventory.
More information is available at www.BizAuctions.com. Investors and media can receive a free investor kit for BizAuctions, Inc. by contacting Investor Relations at investors@BizAuctions.com or (800) 961-3275. A virtual tour of BizAuctions' facilities and flash video presentation can be viewed at www.bizauctions.com/tour.shtml.
The Company encourages the public to read the above information in conjunction with its year-end 10-KSB for December 31, 2006, and the third Quarter 10-QSB for September 30, 2007. The financial statements can be viewed at www.sec.gov.
PURPLE BEVERAGE COMPANY (OTCBB: PPBV)
"Up 46.84% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/PPBV.php
Purple Beverage Company, Inc., an anti-oxidant beverage company, engages in the development, marketing, and distribution of a functional beverage product in the United States. The company offers a beverage product under the brand name Purple, which contains anti-oxidants sourced from seven different fruits for the new age/functional beverage consumer category. The company was founded in 2007 and is based in Fort Lauderdale, Florida.
PPBV News:
February 4 - Purple Beverage Company Signs with Morgan & Sampson USA
Purple to Appear Nationwide on Major Store Shelves
Purple Beverage Company, Inc. (OTCBB: PPBV) announced that it has been chosen by Morgan & Sampson as a new entry in its roster of well-known, well-respected household brands. Morgan & Sampson USA is a multi-faceted consumer product broker whose territory encompasses the entire United States.
Backed by an 87-year history of growth and service, Morgan & Sampson USA (M&S USA) represents a wide array of products ranging from pharmaceutical items to consumables. With nine offices nationwide and an additional office in the UK, M&S USA services some of the largest chains in the country, including well-known store giants Kroger, Safeway, Albertson's, Costco, Longs Drugs and many more national retailers. M&S USA's selection of products includes such household names as Kleenex(r), Sunbeam(r), Rival(r), Bremner-Ralston(r), RyKrisp Crackers(r) and Remington(r), and for these and other quality goods, M&S USA develops and implements retail placement strategies that maximize sales and economic returns for both the product manufacturer and the retailers.
"We are thrilled to be partnering with Morgan & Sampson USA as part of our national rollout strategy. They are undoubtedly one of the best and most respected consumer brand product brokers in the country," said Ted Farnsworth, Founder and CEO of Purple Beverage Company. "Along with their expertise in representing well-known brands that have been around for years, they have also been instrumental in launching new brands to the marketplace that soon become household names - a fact that excites us greatly. Although Purple has been available in select stores nationwide since the product launched in 2007, our goal has always been to bring this all-natural, healthy and fun beverage to consumers everywhere. Teaming with M&S USA means that Purple will now be as close to many consumers as the shelves of their neighborhood grocery store."
Chip Carter, Chief Executive Officer for Morgan and Sampson USA, added, "After watching Purple gain exceptional traction in the marketplace in such a short period of time, we are extremely excited to add a beverage of Purple's quality to our lineup. With the growing demand for all-natural, functional beverage alternatives, we are confident that the market is ripe for an enthusiastic Purple reception." For more information about Morgan and Sampson USA, visit www.morgansampsonusa.com.
Purple is a unique and invigorating blend of seven of the world's most powerful antioxidant juices, including the exotic acai berry, black cherry, pomegranate, black currant, purple plum, cranberry and blueberry. Combined, these juices result in an all-natural, no-sugar added beverage that is perfect as a stand-alone drink or as part of a healthy fruit smoothie.
Purple is also quickly becoming one of the most trendy antioxidant cocktail choices in nightclubs and lounges where available, as adding alcohol to antioxidant-rich berries increases the potency of the antioxidants, a fact confirmed by researchers from the United States Department of Agriculture and by a study at Kasetsart University in Thailand.
"Purple has met with rave reviews everywhere it has launched," stated Farnsworth. "With the strength of Morgan and Sampson USA's name behind it, our scope of distribution should increase dramatically over the next 60 to 90 days, and countless additional consumers will have access to Purple."
Since debuting in select cities coast to coast in 2007, Purple has been praised by such high-profile publications as Health Magazine and Family Circle.
Purple can be found in health food stores, restaurants, delis, drug stores, supermarkets and convenience stores in select locations, including New York, Los Angeles, Miami and Hawaii. In February, it became available in select GNC stores, and look for it nationwide in early 2008. For more information, visit www.drinkpurple.com.
S3 INVESTEMENT COMPANY NEW (OTC: SIVC)
"Up 40.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/SIVC.php
S3 Investment Company, Inc. (www.s3investments.com) is a holding company with two subsidiaries doing business in the China market. S3 holds a 100% equity interest in Redwood Capital (www.redwoodcapinc.com), which assists private Chinese companies in accessing U.S. capital markets by utilizing a network of investment banking relationships to achieve reverse merger transactions, and a 51% equity interest in SINO UJE (www.sinouje.com), a non-stocking distributor of medical and industrial high-tech products to markets throughout China.
SIVC News:
February 5 - S3 Investment Company Secures Full Operational Financing for 2008 and Implements Strategy for Re-Listing on the OTCBB
S3 Investment Company, Inc. (OTC: SIVC), a holding company with two subsidiaries doing business in the China market, announced that it has received a financing commitment, which results in the S3 being fully funded for 2008 and is implementing a strategy by which the company will apply for reinstatement to the Over-the-Counter Bulletin Board (OTCBB) market. The funding covers all corporate expenses for the 2008 calendar year and would eliminate the need for any equity transactions to finance S3 operations for the year.
As part of the financing terms, S3 will complete the audited financial reports required to file for an OTCBB listing. The audited financials to be filed are expected to include annual reports for the 2006, 2007 and 2008 calendar years.
"We are pleased to have received the financing commitment that will cover all corporate expenses for 2008 and eliminate the need to use S3 stock as a funding resource for the year," stated Jim Bickel, chairman and chief executive officer of S3 Investment Company. "The deal flow that has been established by our Redwood Capital subsidiary, which includes the recently closed Dalian Chuming transaction, as well as current clients HaiJai Metallurgical Machinery Manufacturing and Wuhan International Trade College, provides significant anticipated value based on equity participation in each closed transaction. This, and the continued growth of our SINO UJE subsidiary, is expected to make 2008 another strong year for S3."
Redwood Capital participated in a recently closed acquisition transaction involving Dalian Chuming, a pork processing company with USD $70.4 million in sales in 2006, and USD $89.7 million in unaudited sales in the first three quarters of 2007. Energroup Holdings Corporation, a publicly traded Nevada corporation, acquired all of the issued and outstanding capital stock of Precious Sheen Investments Limited, a British Virgin Islands corporation ("PSI") and parent company of PRC-based Dalian Chuming. Energroup Holdings Corporation is traded under the symbol "ENHD."
S3 recently announced that the company's Board of Directors had met and began formulating a plan to dividend shares of the stock of Redwood Capital's reverse merger clients to S3 shareholders of record at a future date. Further details and plans to implement such a strategy are expected to be discussed as they are developed.
To sign up to receive information by email directly from S3 Investment Company when new press releases, investor newsletters, SEC filings or other information is disclosed, visit www.s3investments.com/investors.
VASOMEDICAL INCORPORATED (OTCBB: VASO)
"Up 38.46% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/VASO.php
Vasomedical, Inc. engages in the design, manufacture, marketing, and supporting of EECP external counterpulsation systems for the treatment of diseases of the cardiovascular system. Its EECP therapy system is indicated for use in cases of stable or unstable angina, congestive heart failure, acute myocardial infarction, and cardiogenic shock. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and helps to restore systemic vascular function; and increases blood flow and oxygen supply to the heart muscle and other organs, and decreases the heart's workload and need for oxygen. The company provides its EECP equipment, treatment guidance, and a staff training and equipment maintenance program to hospitals, clinics, and physician private practices. Vasomedical sells EECP therapy systems in the United States through a direct and indirect sales force; and distributes its product internationally through a network of independent distributors. The company was founded in 1987 and is headquartered in Westbury, New York.
VASO News:
February 4 - Vasomedical Awarded New Patent for Automatic Regulation of Pressure During EECP(R) Therapy
Vasomedical, Inc. ("Vasomedical") (OTC: VASO), a world leader in the noninvasive treatment of cardiovascular diseases, announced that the United States Patent and Trademark Office has issued a new patent to Vasomedical on January 1, 2008. This new patent, US 7,314,478 B2 is for technology that automatically controls and precisely maintains the inflation and deflation pressures within the cuffs during enhanced external counterpulsation therapy. The patent also provides for a method to automatically release all applied pressure to the atmosphere in the event of a system or power failure as a safety measure to avoid injury to the patient.
At the start of treatment, the therapist selects the optimal inflation pressure for the patient to comfortably receive effective therapy; the technology then fully controls and maintains, with accuracy, the proper inflation and deflation pressures throughout the treatment.
"Control and maintenance of optimal pressure during EECP(r) treatment is essential to the effectiveness of this therapy for the high percentage of patients that may have irregular or premature heart beats," remarked Dr. John Hui, president and chief executive officer of Vasomedical and inventor of the patent. "This patent is critical to our ability to produce a completely automatic EECP(r) therapeutic system which is capable of providing maximal safety and effectiveness to patients."
"Vasomedical has devoted substantial efforts in clinical studies to enable us to understand the important physiological parameters that guide us in the development of our EECP(r) systems." Dr. Hui continued to state, "The methods covered by this patent have been engineered into our current TS4 and Lumenair models. Vasomedical will continue to develop intellectual properties in its drive to produce the best quality products for the benefit of patients suffering from cardiovascular disease, further demonstrating Vasomedical's leadership position in the noninvasive treatment arena and its commitment to increase shareholder value."
ABOUT VASOMEDICAL AND EECP(r) THERAPY
Vasomedical, Inc. develops, manufactures and markets EECP(r) therapy systems to deliver its proprietary form of enhanced external counterpulsation therapy. EECP(r) therapy is a noninvasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen. Function of the endothelium, the inner lining of blood vessels throughout the body, is also improved, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, and improve exercise performance and quality of life for thousands of people worldwide. For more information visit www.vasomedical.com.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
